D57.452 Sickle-cell thalassemia beta plus with splenic sequestration

Name of the Condition

• Sickle-cell thalassemia beta plus with splenic sequestration

Summary

Sickle-cell thalassemia beta plus with splenic sequestration is a genetic blood disorder resulting from the co-inheritance of sickle cell disease and beta plus thalassemia mutations. It causes red blood cells to become abnormal in shape and function, leading to complications such as anemia, pain, and organ damage. The presence of splenic sequestration indicates a severe, acute phase where red blood cells become trapped in the spleen, potentially causing rapid splenic enlargement and hypovolemia.

Causes

Sickle-cell thalassemia beta plus arises from co-inheritance of mutations in the hemoglobin gene (HBB). One parent contributes a sickle cell mutation, while the other contributes a beta plus thalassemia mutation. This combination alters hemoglobin structure, resulting in sickle-shaped red blood cells and reduced hemoglobin production. Splenic sequestration occurs when these abnormal cells aggregate in the spleen, leading to trapping and pooling of blood.

Risk Factors

• Family history of sickle-cell disease or thalassemia
• Ethnic backgrounds with higher prevalence of these conditions (e.g., Mediterranean, Middle Eastern, Indian, or African descent)
• Inheriting one sickle cell gene and one beta plus thalassemia gene increases the risk of passing the disorder to offspring
• Prior episodes of splenic sequestration or splenomegaly
• Age (more common in young children before splenic autoinfarction)

Symptoms

• Sudden, painful enlargement of the spleen (splenomegaly)
• Rapid drop in hemoglobin levels (severe anemia)
• Weakness, dizziness, or fainting due to hypovolemia
• Abdominal pain or fullness
• Pale skin or mucous membranes
• Rapid heart rate (tachycardia)
• Low blood pressure (hypotension) in severe cases

Diagnosis

Diagnosis involves blood tests to identify sickle-shaped red blood cells, hemoglobin electrophoresis to confirm beta plus thalassemia, and imaging (e.g., ultrasound) to assess splenic size. A rapid decline in hemoglobin with splenic enlargement, especially in a patient with known sickle-cell thalassemia beta plus, supports the diagnosis. Additional tests may include reticulocyte count and blood smear to evaluate red blood cell morphology.

Treatment Options

Treatment focuses on managing acute splenic sequestration and preventing complications. Interventions may include blood transfusions to restore hemoglobin levels, hydration, and pain management. In severe or recurrent cases, splenectomy (surgical removal of the spleen) may be considered. Long-term management involves regular monitoring and preventive measures to avoid future episodes.

Prognosis and Follow-Up

Prognosis depends on the severity of the sequestration episode and timely intervention. Acute episodes can be life-threatening if not treated promptly. Follow-up care includes regular hemoglobin checks, monitoring for splenic size, and education on recognizing early signs of recurrence. Patients with a history of splenic sequestration require ongoing surveillance, especially in children before splenic autoinfarction occurs.

Complications

• Severe anemia leading to hypovolemic shock
• Splenic rupture (rare but possible with extreme enlargement)
• Increased risk of infections (especially after splenectomy)
• Chronic organ damage from repeated sequestration episodes
• Delayed growth or development in children

Lifestyle & Prevention

• Maintain regular medical follow-ups to monitor hemoglobin and splenic status
• Avoid activities that may increase the risk of injury to the abdomen
• Stay hydrated and manage infections promptly
• Educate caregivers (especially for children) on recognizing symptoms of splenic sequestration
• Follow preventive measures for sickle cell complications, such as vaccinations and avoiding triggers for vaso-occlusive crises

When to Seek Professional Help

Seek immediate medical attention if symptoms of splenic sequestration occur, including sudden abdominal pain, weakness, dizziness, or pale skin. Prompt evaluation is critical to prevent severe anemia or shock. Contact a healthcare provider if there are signs of infection, unexplained fatigue, or rapid changes in health status.

Tips for Medical Coders

Code D57.452 is specific to sickle-cell thalassemia beta plus with splenic sequestration. Documentation should clearly indicate the presence of splenic sequestration as a complication, including clinical findings (e.g., splenomegaly, hemoglobin drop) and any interventions (e.g., transfusions, imaging). Ensure the diagnosis aligns with the co-inheritance of sickle cell and beta plus thalassemia mutations to support accurate coding.